Avesta Biotherapeutics & Research

Avesta Biotherapeutics & Research (ABR) is a biopharmaceutical company headquartered in Bangalore, India, established as a strategic joint venture between Avesthagen Limited and Cipla Limited. The company specializes in the development and manufacturing of biosimilars, monoclonal antibodies, and fusion proteins, with a primary focus on therapeutic areas such as oncology and immunology. ABR's pipeline includes biosimilar candidates for major biologics including etanercept, infliximab, and bevacizumab, aimed at treating conditions like rheumatoid arthritis and various cancers. The company operates a cGMP-compliant manufacturing facility and has expanded its capabilities through the acquisition of Siegfried Biologics in Germany. Founded in 2005, Avesta Biotherapeutics & Research leverages Avesthagen's R&D expertise and Cipla's extensive commercial infrastructure to bring affordable biotherapeutic solutions to the global market.